GlassScriptPhysician profile
Matthew Krafft
NPI 1477965135
$27,532.66
in general payments reported to CMS, 2019-2025
11 companies · $749 in 2025
The $749 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2021: $25K · 2022: $43.69 · 2023: $383 · 2024: $466 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $25,556.38 | 2021-2025 | Exalt Model D, Overstitch Nxt Endoscopic Suturing System, Overstitch Endoscopic Suturing System |
| Olympus Corporation of The Americas | $873.89 | 2019 | |
| Medtronic, INC. | $567.29 | 2024-2025 | Barrx, Nexpowder, Gi Genius |
| Conmed Corporation | $164.45 | 2025 | Conmed Biliary |
| Abbvie INC. | $126.41 | 2019-2025 | |
| Steris Corporation | $122.16 | 2023 | |
| Mallinckrodt Hospital Products INC. | $29.99 | 2024 | Terlivaz |
| Janssen Biotech, INC. | $29.27 | 2025 | Tremfya |
| Abbott Laboratories | $23.11 | 2025 | Amplatzer Amulet |
| Madrigal Pharmaceuticals | $20.02 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $19.69 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Krafft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.